Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute.
This study was undertaken to reveal the trends of prostate cancer and the outcome of treatment modalities for each disease stage in patients in a single institute over a 10-year period. From January 1994 through December 2003, 420 consecutive patients with previously untreated and histologically confirmed prostate cancer were analyzed for annual distributions of disease stages and treatment modalities and for long-term clinical progression-free survival, prostate cancer-specific survival, and prostate-specific antigen (PSA) failure-free survival rates for each stage and treatment modality. Annual trends showed that the number of patients, especially those with clinically localized cancer, increased dramatically. The 5-year disease-specific survival rates for patients with clinically localized disease were 100 percent for all treatment modalities, including hormonal therapy alone. Patients with PSA levels less than 10 ng/ml showed an 81 percent 5-year PSA failure-free survival rate with radical prostatectomy. Stage C patients treated by surgery or radiation-based therapy with concomitant hormonal therapy obtained 93 percent and 100 percent cause-specific survival rates, respectively, and those treated by hormonal therapy alone showed a 79 percent rate. The number of patients with localized prostate cancer was increasing in this decade. While long-term hormonal therapy alone was highly efficient in controlling localized prostate cancer, radical therapies in conjunction with neo-adjuvant hormonal therapy produced better survival rates in cases of locally advanced disease.
Edamura
Kohei
K
Department of Urology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan.
Saika
Takashi
T
Senoh
Takashi
T
Koizumi
Fumihito
F
Manabe
Daisuke
D
Ebara
Shin
S
Kaku
Haruki
H
Yokoyama
Teruhiko
T
Abarzua
Fernando
F
Nagai
Atsushi
A
Nasu
Yasutomo
Y
Tsushima
Tomoyasu
T
Kumon
Hiromi
H
D000047:Academies and Institutes; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome